Successful use of Impella 5.5 to manage cardiogenic shock complicated by COVID-19.

The findings reported here demonstrate successful use of an Impella 5.5 to improve native heart function in refractory cardiogenic shock and further indicate its use as an option for those in acute decompensated heart failure who have tested positive for COVID-19 infection.